Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186.

Authors:
Danielle E Dettling Eilene Kwok Lucy Quach Aakash Datt Jeremiah D Degenhardt Anand Panchal Pui Seto Jessica L Krakow Russell Wall Brian J Hillier Ying Zhu Maia Vinogradova Robert B DuBridge Chad May

J Immunother Cancer 2022 Jun;10(6)

Oncology Drug Development Unit, Takeda Development Centers America, Inc (TDCA), Lexington, Massachusetts, USA.

Background: Despite clinical success with T cell engagers (TCEs) targeting hematological malignancies, achieving a safe and efficacious dose in patients with solid tumors remains challenging. Due to potency, low levels of target antigen expression on normal tissues may not be tolerated. To overcome this, we engineered a novel conditionally active TCE design called COBRA (nditional ispecific edirected ctivation). Administered as prodrugs, COBRAs bind to cell surface antigens on both normal and tumor tissues but are preferentially activated within the tumor microenvironment.

Methods: A COBRA was engineered to target EGFR, TAK-186. The potency of precleaved TAK-186 relative to a non-cleavable control was assessed in vitro. Mice bearing established solid tumors expressing a range of EGFR levels were administered a single bolus of human T cells, and concurrently treated with TAK-186 and associated controls intravenously. We assessed the plasma and tumor exposure of intact and cleaved TAK-186.

Results: TAK-186 shows potent redirected T cell killing of antigen expressing tumor cells. In vivo efficacy studies demonstrate regressions of established solid tumors, dependent on intratumoral COBRA cleavage. Pharmacokinetic studies reveal TAK-186 is stable in circulation, but once activated is rapidly cleared due to loss of its albumin-binding half-life extension domain.

Conclusions: The studies shown support the advancement of TAK-186, and the pursuit of additional COBRA TCEs for the treatment of solid tumors.

Download full-text PDF

 Source
http://dx.doi.org/10.1136/jitc-2021-004336DOI Listing
June 2022

Publication Analysis

Top Keywords

solid tumors
20
established solid
12
conditionally active
8
tak-186
7
solid
5
tumors
5
treatment solid
4
administered single
4
vitro mice
4
mice bearing
4
bearing established
4
tumors expressing
4
expressing range
4
range egfr
4
egfr levels
4
levels administered
4
bolus human
4
single bolus
4
control assessed
4
human cells
4

Keyword Occurance

Similar Publications

Use of circulating tumour DNA in nasopharyngeal carcinoma to detect minimal residual disease.

Authors:
Bipin Ghimire Emma Herrman Ujjwal Karki Mohammad Muhsin Chisti

BMJ Case Rep 2022 Jun 24;15(6). Epub 2022 Jun 24.

Hematology and Medical Oncology, Oakland University William Beaumont School of Medicine, Troy, Michigan, USA.

Circulating tumour DNA (ctDNA) is defined as short DNA sequences shed by tumour cells into the systemic circulation. A promising use of ctDNA includes the detection of minimal residual disease (MRD) and is currently being studied in multiple types of solid tumours. Literature for the use of individualised ctDNA in nasopharyngeal carcinoma (NPC) is not available, although circulating Epstein-Barr virus DNA level is validated as a prognostic factor. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer.

Authors:
Eugenia Girda June Hou David Nelson Malcolm Finlayson Alexandre Buckley de Meritens Marina Chekmareiva Aliza Leiser Mihae Song Ruth Stephenson Nancy Chan Ana I Tergas Reena Vattakalam Jason D Wright Hua Yu Antons Martincuks Adrian Kohut Joycelynne Palmer Lorna Rodriguez-Rodriguez

Int J Gynecol Cancer 2022 Jun 24. Epub 2022 Jun 24.

City of Hope National Medical Center, Duarte, California, USA

Objective: Preclinical evidence and early clinical trials have demonstrated the activity of SPL-108, a targeted agent that inhibits CD44 mediated induction of multidrug resistance specifically to paclitaxel and platinum agents. We conducted a phase I, open label, dose escalation study of the safety and tolerability of the combination of SPL-108 with weekly paclitaxel in patients with platinum resistant CD44+ ovarian, primary peritoneal, or fallopian tube cancer.

Methods: Patients with platinum resistant histologically proven epithelial ovarian, primary peritoneal, or fallopian tube cancers and measurable disease according to RECIST (Response Evaluation Criteria in Solid Tumours) version 1. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Amino acid coordination complex mediates cisplatin entrapment within PEGylated liposome: an implication in colorectal cancer therapy.

Authors:
Elaheh Mirhadi Fatemeh Gheybi Nadia Mahmoudi Maliheh Hemmati Fatemeh Soleimanian Atefeh Ghasemi Anis Askarizadeh Mehrdad Iranshahi Mahmoud Reza Jaafari Seyedeh Hoda Alavizadeh

Int J Pharm 2022 Jun 21:121946. Epub 2022 Jun 21.

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:

Cis-Diaminedichloroplatinum (cisplatin, CDDP) remained among the most widely used anti-cancer agents; however, management of the dose-limiting side effects is still a great hurdle to its therapeutic potential. In the framework of this investigation, novel approach was developed for CDDP encasement within liposome based on the formation of a coordination bond between the platinum (II) atom and a carboxylic group in aspartic acid (AA) and glutamic acid (GA). We have also compared two methods of preparation based on equilibration and conventional lipid film hydration. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Toll-like receptor 3 (TLR3) overexpression induces invasion of prostate cancer cells, whereas its activation triggers apoptosis.

Authors:
Ximena Maria Muresan Eva Slabáková Jiřina Procházková Stanislav Drápela Radek Fedr Markéta Pícková Ondřej Vacek Ráchel Víchová Tereza Suchánková Jan Bouchal Daniela Kürfürstová Milan Král Tereza Hulínová Radek Paus Sýkora Vladimír Študent Václav Hejret Wytske M van Weerden Martin Puhr Václav Pustka David Potěšil Zbyněk Zdráhal Zoran Culig Karel Souček

Am J Pathol 2022 Jun 21. Epub 2022 Jun 21.

Department of Cytokinetics, Institute of Biophysics of Czech Academy of Sciences, Královopolská 135, 612 65 Brno, Czech Republic; International Clinical Research Center, St. Anne's University Hospital in Brno, Pekařská 53, 656 91 Brno, Czech Republic; Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic. Electronic address:

Toll-like receptor 3 (TLR3) is an endosomal receptor expressed in several immune and epithelial cells. Recent studies have highlighted its expression also in solid tumours, including prostate cancer (PCa), and described its role mainly in the pro-inflammatory response and induction of apoptosis. It has been found upregulated in some castration-resistant prostate cancers. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Sex and cancer immunotherapy: Current understanding and challenges.

Authors:
Laura Pala Tommaso De Pas Chiara Catania Giuseppe Giaccone Alberto Mantovani Saverio Minucci Giuseppe Viale Richard D Gelber Fabio Conforti

Cancer Cell 2022 Jun 17. Epub 2022 Jun 17.

Division of Melanoma, Sarcomas and Rare Tumors, European Institute of Oncology, Milan, Italy. Electronic address:

Recent evidence highlights patients' sex relevance in antitumor immune response through a complex interaction-among hormones, genes, behaviors, and the microbiome-that affects both innate and adaptive immune functions, as well as immune evasion mechanisms. These complex interactions ultimately influence the efficacy and toxicity of immune checkpoint inhibitors in solid tumors. Read More

View Article and Full-Text PDF
June 2022
Similar Publications
}